Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LNSR Stock Forecast 2025-2026
$11.20
Current Price
$133.78M
Market Cap
Buy 0
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to LNSR Price Targets
+33.9%
To High Target of $15.00
+33.9%
To Median Target of $15.00
+33.9%
To Low Target of $15.00
LNSR Price Momentum
+10.0%
1 Week Change
+5.7%
1 Month Change
+45.5%
1 Year Change
+25.3%
Year-to-Date Change
-35.3%
From 52W High of $17.31
+57.1%
From 52W Low of $7.13
📊 TOP ANALYST CALLS
Did LNSR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if LENSAR is one of their latest high-conviction picks.
Latest LNSR Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, LNSR has a neutral consensus with a median price target of $15.00 (ranging from $15.00 to $15.00). The overall analyst rating is N/A (N/A/10). Currently trading at $11.20, the median forecast implies a 33.9% upside. This outlook is supported by 0 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Frank Takkinen at Lake Street, projecting a 33.9% upside. Conversely, the most conservative target is provided by Frank Takkinen at Lake Street, suggesting a 33.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LNSR Analyst Ratings
0
Buy
2
Hold
0
Sell
LNSR Price Target Range
Low
$15.00
Average
$15.00
High
$15.00
Current: $11.20
Latest LNSR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LNSR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 24, 2025 | Lake Street | Frank Takkinen | Hold | Downgrade | $15.00 |
| Feb 28, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $16.00 |
| Mar 19, 2024 | Lake Street | Buy | Initiates | $8.00 | |
| Nov 22, 2021 | BTIG | Ryan Zimmerman | Buy | Initiates | $15.00 |
| Feb 24, 2021 | SVB Leerink | Outperform | Initiates | $N/A |
Lensar Inc. (LNSR) Competitors
The following stocks are similar to LENSAR based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lensar Inc. (LNSR) Financial Data
Lensar Inc. has a market capitalization of $133.78M with a P/E ratio of -4.1x. The company generates $59.14M in trailing twelve-month revenue with a -87.1% profit margin.
Revenue growth is +5.7% quarter-over-quarter, while maintaining an operating margin of -16.1% and return on equity of -422.3%.
Valuation Metrics
Market Cap
$133.78M
Enterprise Value
$133.57M
P/E Ratio
-4.1x
PEG Ratio
0.0x
Price/Sales
2.3x
Growth & Margins
Revenue Growth (YoY)
+5.7%
Gross Margin
+42.2%
Operating Margin
-16.1%
Net Margin
-87.1%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+12.6%
Current Ratio
1.2x
Debt/Equity
-0.1x
ROE
-422.3%
ROA
-8.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lensar Inc. (LNSR) Business Model
About Lensar Inc.
What They Do
Develops advanced laser technology for cataract surgery.
Business Model
Lensar Inc. generates revenue by selling its flagship Lensar Laser System, which enhances the precision of cataract surgeries. The company targets hospitals and surgical centers, offering innovative medical technology solutions that improve surgical outcomes and patient safety, thereby positioning itself as a leader in the ophthalmology sector.
Additional Information
Headquartered in Orlando, Florida, Lensar is committed to ongoing research and development to maintain its competitive edge and contribute to advancements in eye health. The company plays a significant role in setting new surgical standards and improving patient care in a rapidly growing market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
140
CEO
Mr. Nicholas T. Curtis
Country
United States
IPO Year
2020
Website
www.lensar.comLensar Inc. (LNSR) Latest News & Analysis
Latest News
Quick Summary
LENSAR, Inc. reported a 77% growth in its installed base of ALLY Robotic Cataract Laser Systems in Q3 2025, with 18 systems placed and a backlog of 18 pending installations.
Why It Matters
LENSAR's 77% growth in installed ALLY Systems signals strong demand and potential revenue increases, enhancing investor confidence in the company's market position and future profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
LENSAR, Inc. (Nasdaq: LNSR) announced that its board granted 660 restricted stock units to three newly-hired non-executive employees.
Why It Matters
The granting of RSUs to new hires can signal confidence in the company's growth and attract talent, potentially leading to enhanced performance and shareholder value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Lensar (LNSR) Q2 Revenue Rises 10%
4 months ago
Quick Summary
Lensar (LNSR) reported a 10% increase in revenue for Q2.
Why It Matters
Lensar's 10% revenue growth in Q2 indicates strong demand and potential for future profitability, positively influencing investor sentiment and stock performance.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
As of June 30, 2025, 18 ALLY Robotic Cataract Laser Systems have been installed, with an additional backlog of 18 systems awaiting installation.
Why It Matters
The placement of 18 ALLY Systems and the additional backlog indicate strong demand and potential revenue growth for the company, signaling positive momentum in the medical technology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
LENSAR, Inc. is set to be sold to Alcon Inc. for $14.00 per share, plus a contingent value right of up to $2.75 per share, pending certain milestones. KSF is investigating the deal.
Why It Matters
The proposed sale of LENSAR to Alcon offers shareholders immediate cash and potential future value, impacting LENSAR's stock price and investor returns during the transaction process.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
14 ALLY Robotic Laser Cataract Systems were installed in Q1 2025, with a backlog of 24 systems awaiting installation as of March 31, 2025.
Why It Matters
The deployment of 14 ALLY Systems and a backlog of 24 indicates strong demand and potential revenue growth for the company, signaling positive market momentum and investment opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LNSR Stock
What is Lensar Inc.'s (LNSR) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Lensar Inc. (LNSR) has a median price target of $15.00. The highest price target is $15.00 and the lowest is $15.00.
Is LNSR stock a good investment in 2026?
According to current analyst ratings, LNSR has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LNSR stock?
Wall Street analysts predict LNSR stock could reach $15.00 in the next 12 months. This represents a 33.9% increase from the current price of $11.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lensar Inc.'s business model?
Lensar Inc. generates revenue by selling its flagship Lensar Laser System, which enhances the precision of cataract surgeries. The company targets hospitals and surgical centers, offering innovative medical technology solutions that improve surgical outcomes and patient safety, thereby positioning itself as a leader in the ophthalmology sector.
What is the highest forecasted price for LNSR Lensar Inc.?
The highest price target for LNSR is $15.00 from Frank Takkinen at Lake Street, which represents a 33.9% increase from the current price of $11.20.
What is the lowest forecasted price for LNSR Lensar Inc.?
The lowest price target for LNSR is $15.00 from Frank Takkinen at Lake Street, which represents a 33.9% increase from the current price of $11.20.
What is the overall LNSR consensus from analysts for Lensar Inc.?
The overall analyst consensus for LNSR is neutral. Out of 3 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are LNSR stock price projections?
Stock price projections, including those for Lensar Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 5:44 PM UTC